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BACKGROUND: Motor Neurone Disease MND) is a devastating condition which greatly affects 
patients’ quality of life and limits life expectancy. Health technology appraisals of future 
interventions in MND need robust data on costs and utilities. Existing economic evaluations have 
been noted to be limited and fraught with challenges. 
OBJECTIVE: The aim was to identify and critique methodological aspects of all published economic 
evaluations, cost studies and utility studies in MND.  
METHODS: We systematically reviewed all relevant published studies in English from 1946 until 
January 2016, searching the databases of Medline, EMBASE, Econlit, NHS Economic Evaluation 
Database (NHS EED) and the Health Economics Evaluation Database (HEED). Key data were extracted 
and synthesised narratively. 
RESULTS: A total of 1,830 articles were identified, of which 15 economic evaluations, 23 cost and 3 
utility studies were included. Most economic studies focused on riluzole (n=9). Six studies modelled 
the progressive decline in motor function using a Markov design but did not include mutually 
exclusive health states. Cost estimates for a number of evaluations were based on expert opinion 
and were hampered by high variability and location-specific characteristics. Few cost studies 
reported disease stage specific costs (n=3) or fully captured indirect costs. Utilities in 3 studies of 
MND patients used the EQ-5D questionnaire or standard gamble, but included potentially 
unrepresentative cohorts and did not consider any health impacts on caregivers. 
CONCLUSION: Economic evaluations in MND suffer from significant methodological issues such as a 
lack of data, uncertainty with the disease course and use of inappropriate modelling framework. 
Limitations may be addressed through the collection of detailed and representative data from large 
cohorts of patients. 
 
Key points for decision makers 
• Existing economic evidence in MND is limited with respect to data on resource use, costs, and 
health utilities, as well as how models reflect disease progression 
• Future studies should focus on generating longitudinal data from representative population 
groups; confirming the validity of models in how they represent the natural course of disease 





• The evidence accumulated in this review provides a basis for the advancement of economic 






1. Introduction  
Motor Neurone Disease or Amyotrophic Lateral Sclerosis (hereafter referred to as MND) is a 
progressively degenerative condition. The disease affects the motor neurones in the brain and spinal 
cord which severely impacts patients’ basic functioning such as walking, communication and 
breathing, and can additionally adversely affect cognitive abilities [1]. These impair patients’ health-
related quality of life significantly [2]. Currently treatment for MND is focused on palliative care with 
the aim of sustaining a high quality of life for as long as possible. Estimated survival time from 
diagnosis is between 3 and 5 years [3]. Due to the extent of the disability, patients with MND have 
dependency on carers to help with their daily needs. This need is usually met by partners or family 
members of the patient and, due to the nature of care required, places a significant physical and 
emotional burden on their lives [4]. 
MND is a rare disease with incidence and prevalence rates varying by country and region. A recent 
systematic review of its epidemiology reported European, North American and Asian incidence rates 
of 2.08, 1.8 and 0.46 per 100,000 population per year, respectively [5]. Prevalence rates were 
reported as 5.4, 3.4 and 2.01 per 100,000 population in these regions. In the United Kingdom there 
are an estimated 4,000 people living with MND [6]. 
The economic costs of MND are high, both in terms of direct medical costs to health providers, non-
medical costs incurred by patients and their caregivers, and indirect costs through loss of 
employment. Costs vary over the trajectory of the condition, and are dependent on disease 
manifestation, progression, and duration of survival [7]. To date, however, there has been a limited 
number of economic evaluations of interventions for MND, with the majority focused on riluzole 
which is the only disease-modifying drug currently approved. With the prospect of new treatments 
for MND [8], there will be an increased need for robust economic data and modelling framework for 
assessing their cost-effectiveness. The aim of this article is to systematically review sources of costs 
and utilities, and provide a critique of the data and methods used in economic studies of MND. 
2. Methods 
This review was conducted according to the Centre for Reviews and Dissemination’s (CRD) guidance 
for undertaking reviews in health care [9], and reported with alignment to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline, where applicable [10]. 
2.1 Search Strategy 
Systematic searches were undertaken to identify economic evaluations, studies detailing costs and 





Appendix 1. The databases searched (from 1946 to January 2016) were: Medline, EMBASE, Econlit, 
NHS Economic Evaluation Database (NHS EED), and the Health Economics Evaluation Database 
(HEED). The references of included papers were checked for any further articles for inclusion. 
2.2 Inclusion criteria and study selection 
The review included studies reporting economic evaluations, detailed costs and health utilities 
relating to MND. Studies not published in English were excluded from the review. Titles were 
screened independently by two reviewers. Articles deemed by either reviewer to meet the inclusion 
criteria were screened independently on abstract with any disagreements resolved by a third 
independent reviewer. The full texts were retrieved and assessed according to the inclusion criteria.  
2.3 Data extraction 
Data forms were created for the economic evaluations and cost studies included in the review and 
key details relating to the methods of included studies extracted and tabulated (Tables 1 and 2). Cost 
and utility value data from these studies were also recorded along with the corresponding 2014/15 
value of costs in pounds sterling (GBP) (Table 3). Currency conversions were undertaken using data 
from the International Monetary Fund (IMF) [11] and costs were inflated using the Hospital and 
Community Health Services (HCHS) pay and prices index [12].  
2.4 Analysis of results 
Important methodological features were summarised, and critiqued within a narrative review.  
3. Results 
A total of 1,830 articles were identified, of which 60 were considered potentially relevant and 41 
eligible for inclusion in the review. The PRIMSA flow diagram shows the number of included studies 
at the various stages of the review process (Figure 1). 
-- Insert Figure 1 here – 
3.1 Study characteristics  
The systematic review identified 13 economic evaluations, 2 updates of economic evaluations, 23 
cost studies, and 3 studies reporting health utilities (Tables 1, 2 and 3). 
The majority of economic evaluations were conducted in the UK [16-20,24,26,27] (n=8) followed by 
North America [13,15,22,23] (n=4), Italy [14,21] (n=2) and Israel [25], showing the high 
concentration of studies originating in a few countries. Eight studies reported a cost utility analysis 





carried out a cost-benefit analysis [25]. Eleven evaluations adopted a third party payer perspective, 
such as national health services [13,14,16-21,24,26,27], 1 study adopted a societal viewpoint [25], 
while 3 studies presented results from both perspectives [15,22,23]. More recent economic 
evaluations tended to report only direct medical costs to health service providers. 
Studies focusing solely on costs were predominantly North American 
[28,30,33,34,37,40,43,44,46,48-50] (n=12) or European [31,32,36,38,39,41,42,45,47] (n=9) with two 
from Asia [29,35]. Cost studies adopted a health services perspective [28,31,35,39,43,44,46-48] 
(n=9), societal perspective [33,40,41,45,49] (n=5) or both [29,30,32,34,36-38,42,50] (n=9). Studies 
reported costs for a variety of categories, including: treatments [30,32-34,36,37,41,42,44,45,47,48] 
(n=12), places or methods of delivering care [28,29,31,35,38,39,43,46] (n=8), home ventilation 
[49,50] (n=2) and mobility devices [40]. However, only 3 studies reported disease stage specific costs 
[29,42,47].  
 
Studies of health state utility reported disease stage utilities by five (mild, moderate, severe, 
terminal and death) [51,52], or two (mild and severe) [42] health states. All studies elicited utilities 
from patients with MND, based on structured interviews with MND patients [51,52], or from a postal 
questionnaire [42]. These used a combination of the EQ-5D-3L, visual analogue scale (VAS) and 
standard gamble to measure utility. 
-- Insert Tables 1 and 2 here -- 
3.2 Modelling methodology  
Eight studies, including the more recent evaluations, used Markov architecture which allow for 
progressive decline in motor function to be modelled [15-20,22,23]. The models attach costs and 
utilities to health states and allow patient cohorts to pass through states until they reach the 
(absorbing) death state or a pre-determined severely low functioning level. Health states within 
these models were defined by adaptation of Rivere et al. [53] who first modelled MND using the 
Markov model [15-20], Appel ALS scores [22] or according to forced vital capacity scores (FVC) [23]. 
Transition probabilities of subjects through the various health states were calculated using data from 
randomised control trials of riluzole [15-20], recombinant human insulin-like growth factor-1 (rhlGF-
1) [22], and brain-derived neurotrophic factor (BDNF) [23].  
Models used various techniques to estimate survival beyond the data available from randomised 
controlled trials (RCTs). Three studies used a linear function [16-18], and one an exponential function 





authors, they are not the correct functional form for survival analysis. The constant hazard rate 
model, which gives the exponential distribution, assumes the property of no-aging [58]. One study 
used a Weibull model [20] (based on a power hazard rate model). One study used a Gompertz model 
(exponential hazard rate model), without presenting goodness of fit [21], and one study used both a 
Weibull and a Gompertz model [19] to explore differences in model fit. 
3.3 Resource use and costs 
Twenty-two studies reported direct costs only [13,14,16-21,24,26-28,31,35,39,40,43-48], while 16 
reported both direct and indirect costs [15,22,23,25,29,30,32-34,36-38,41,42,49,50].  
Studies which included direct costs estimated resource use from medical records [13-
15,28,31,32,37-39,43] (n=10), RCTs [19-27] (n=9), surveys [30,37,40,42,45,49,50] (n=7), utilization 
patterns based on consultation with neurologists with MND expertise [16-18,47,48] (n=5), national 
databases [36,46] (n=2), structured interviews with patients [33,41] (n=2), insurance claim data [34] 
and a mixture of medical records and insurance claim data [35]. Indirect costs were obtained via 
patient surveys [15,23,30,32,34,37,38,42,49,50] (n=10) and interviews [22,29,33,41] (n=4), and 
national databases [25,36] (n=2). 
Unit costs came from institutional records [13,14,28,29,31-33,35,38,39,43,45,46] (n=13), national 
databases [15,21,24-27,36,37,42,44] (n=10), the published literature [16-20,23] (n=6), surveys 
[30,40,41,49,50] (n=5), consultation with MND experts [47,48] (n=2), insurance claim data [34] and 
estimation of drug costs from the manufacturer [22]. 
Some studies defined standard care costs [16,19,20,22,25,27] (n=6), but descriptions varied by 
location and setting. 
Indirect unit costs were gathered by surveys [22,23,29,30,33,34,38,41,49,50] (n=10), national 
databases [15,36,37,42] (n=4) and using the national minimum [32] and average wage [25].  
Key cost data used in economic evaluations in MND are presented in Table 3. Many of the cost 
inputs originate from the same sources, suggesting a limited evidence base [16-20]. Furthermore, 
costs varied by location, with the annual price of riluzole, for example, reported as £6,429 in the 
United Kingdom and £9,487 in the United states (2014/15 adjusted values in £GBP). Table 4 presents 
the main data from cost studies in MND. Costs and cost categories include length of hospital stays 
[35,43,46], ventilation [30,49,50], complementary medicines [45] and mobility [40]. Differences in 
costs within countries may be attributed to type of treatments considered, methods of data 





challenges of generalising results, with the need for more detailed and encompassing cost of illness 
studies. 
-- Insert Tables 3 and 4 here -- 
3.4 Health state utilities  
Eleven studies included the use of health state utility values (HSUVs), of which 6 [15-20] took their 
values from Kiebert et al. [51] who elicited utilities based on standard gamble using structured 
interviews in the UK. However, this study is limited in size, with only 77 MND patients involved and 
with some health states being represented by as few as 15 patients. Two other studies used 
hypothetical utility values which were not based on any empirical evidence but rather, intended for 
illustrative purposes [23,24]. One study estimated utilities using the standard gamble technique 
administered to a panel of healthcare professionals with experience of treating patients with MND 
[22]. A study in Spain used postal administration of the EQ-5D-3L and EQ-Visual Analogue Scale (VAS) 
in a sample of 36 patients [42]. The most recent utility study, which was set in the UK with a sample 
of 214 patients, also used the EQ-5D-3L along with the EQ-VAS, to elicit utilities longitudinally [52].  
Studies which included HSUVs varied in their description of health states.  A five-stage model was 
used in Kiebert et al. [15-20,51] based on the earlier work of Rivere et al. [53]. The full definitions of 
health states are presented in Box 1. Jones et al. [52] used the King’s ALS clinical stage framework 
consisting of five states; stage 1: diagnosis and involvement of 1st region, stage 2: involvement of 2nd 
region, stage 3: involvement of 3rd region, stage 4: need for intervention (gastrostomy or non-
invasive ventilation) and stage 5: death. Ackerman et al [22] used a five state model defined by 
Appel ALS scores which cover aspects of speech, respiratory function, swallowing, dressing and 
feeding, need for assistive device, work status and medical care. By contrast Ringel et al [23] used a 
four health stage model based solely on forced vital capacity scores (FVC). López-Bastida et al. [42] 
used a simple two-stage classification of the disease with patients either in the mild state (not in 
need caregiver help), and the severe state (in need of caregiver help). 
Health state utility data in the economic evaluations came from a limited number of sources [15-
20,22], with some reliant on hypothetical data [23,24] highlighting a lack of evidence in this area 
(Table 3).  Furthermore, as descriptions of health states are not uniform [15-20,22,23], utility values 
varied significantly, especially in some progressively low functional states. In the most recent UK 
evaluations [16-20], the terminal state value is 0.45, compared with -0.53 in the study by Ackerman 
et al [22]. Differences in health utility values appear to be more divergent than the health 





Box 1. Health states as defined by Rivere et al. [53].  
State 1 (mild). Recently diagnosed; mild deficit in only 1 of 3 regions (i.e., speech, arm, and leg); and 
functionally independent in speech, upper extremity activities of daily living, and ambulation. 
State 2 (moderate). Mild deficit in all 3 regions or moderate to severe deficit in 1 region, while the 
other 2 regions are normal or mildly affected. 
State 3 (severe). Needs assistance in 2 or 3 regions; speech is dysarthric and/or patient needs 
assistance to walk and/or needs assistance with upper extremity activities of daily living. 
State 4 (terminal). Non-functional use of at least 2 regions and moderate or non-functional use of 
the third region. 
 
3.5 Uncertainty analysis 
Most economic evaluations considered parameter uncertainty by application of one-way sensitivity 
analysis around benefits/utilities [16-22,24] (n=9), costs [16-20,25] (n=6) and tolerance of patient 
cohorts to treatment [15]. Three studies performed two-way sensitivity analysis to jointly assess the 
contribution of both costs and benefits/utilities on cost-effectiveness [16-18], while only one study 
carried out a full probabilistic sensitivity analysis [23]. Scenario analyses considered uncertainty in 
costs, health benefits and survival [21,26] (n=2). Two studies attempted to account for structural 
uncertainty with alternative models [19,21], while another study assessed the impact of different 
patient demographics on cost-effectiveness (of riluzole) [26]. Uncertainty analysis in the studies 
showed that the main drivers of cost effectiveness in MND treatments were drug costs and 
estimated extension in survival. 
4. Discussion 
With the prospect of new treatments for MND on the horizon, including the neuroprotective agent 
edaravone, tyrosine kinase inhibitor masitinib and gene and stem cell therapies [59-62], there will be 
an increased need for robust data and modelling framework to assess their cost-effectiveness. Most 
economic evaluations are based on Markov models with disease-specific stages which aim to trace 
disease progression and its effects on patients and their use of healthcare resources. The often used 
five-stage disease progression model [15-20,51,53] has methodological issues with respect to its 
clinical classification system of health states.  It conflates recency of diagnosis with severity of illness 
and would lead to some patients being misplaced in health states which may not reflect the true 





mutual exclusivity.  The Kings ALS clinical staging model, as used in Jones et al. [52], provides health 
state descriptions which are mutually exclusive, and therefore potentially making it more 
appropriate for use in Markov modelling. 
Costs can vary considerably between stages of MND [29,42,47]. However, only a few studies have 
reported disease stage specific costs. Munsat et al. [47] is the most cited among UK economic 
evaluations, but the estimates from this analysis are based on resource utilization taken from 
interviews with four neurologists with experience of treating MND, and needs updating. The authors 
highlight the variation in cost estimates between each expert, reflecting differences in clinical 
practice. Economic evaluations included in our review did not consider changes to the annual costs 
of standard palliative care by disease stage as it was claimed that these would be unaffected by 
treatment. This assumption has been untested empirically.  
Several studies have reported or estimated indirect costs associated with MND 
[15,22,23,25,29,30,32--34,36-38,41,42,49,50]. While there are recognised challenges relating to the 
measurement of lost productivity by both patients and their caregivers [63-65], the importance is 
more so in MND as patients have a higher earning potential than the national averages [36], owing 
to the average age of onset peaking around the mid-fifties and the fact that the disease presents 
more in men [1].  
Instruments used to measure the health related quality of life in patients with MND need to be 
sensitive enough to capture changes across the disease course, have the required dimensions which 
apply to the condition and robust psychometric properties. The EQ-5D-3L has been used as a generic 
measure, but concerns have been highlighted over its ability to record an accurate representation of 
the complexity surrounding quality of life (QoL) in MND. The narrow conceptual components of the 
EQ-5D-3L often restricts utility measurement and fails to include symptom characteristics which are 
salient to those with MND, such as respiratory function and communicative ability [66,67].  Issues 
such as sensitivity of the EQ-5D-3L to clinical changes in the disease course and their resulting impact 
on utilities, and floor effects further limit the usefulness of the instrument. One undertaking which 
could help in this regard is using the EQ-5D-5L, which improves the range of responses and mitigates 
the floor effects to some degree [68,69].  
The ALS Utility Index is a disease-specific instrument which has been developed through surveying a 
general population sample, but is yet to be validated in MND patients [70]. This index also focuses 
solely on the physical functioning aspect of MND, with no domain for emotional wellbeing or pain. In 





Patients’ preferences may vary with respect to the management of the different symptoms 
experienced. Direct utility estimation in MND has been limited to the standard gamble approach. 
Kiebert et al. [51] found that utility scores, based on standard gamble, were higher for disease stage 
3 (needs assistance in two or three regions) than disease stage 2 (mild defect in three regions) in the 
ALS Health State Scale; despite the descriptions of disease stage 3 appearing to be significantly 
worse. However, when the same sample of patients completed the EQ-5D-3L questionnaire, the 
results showed a progressive lowering of health stage utilities along the disease course. 
Furthermore, this study elicited significantly different utility score estimations for standard gamble 
and EQ-5D-3L methods. The standard gamble results from this study featured in the riluzole 
manufacture’s submission to National Institute for Health and Care Excellence (NICE) [18], as well as 
the more recent economic evaluations in MND [15-17]. Alternative methods of direct utility 
estimation, such as time trade off or the use of choice-based techniques such as the Discrete Choice 
Experiment (DCE), have hitherto not featured in MND studies. 
MND has important and significant impacts on informal caregivers, such as family members [71-73]. 
While there is debate concerning the inclusion of the QoL effects on carers in economic evaluations, 
and methodological challenges relating to the measurement, valuation and incorporation of QoL 
impacts on carers [63-65], the lack of consideration for carer utilities in MND is apparent. Further 
challenges include consideration of how carers’ productivity is affected by the disease, especially in 
the latter stages of the condition when more help is required. The inclusion of caregiver utilities in a 
cost-effectiveness framework for MND could affect conclusions of economic evaluations of 
treatments if those treatments are near cost-effectiveness threshold values, as was the case for 
riluzole, and prove to impact on carers’ QoL [63].  
The strengths of the review are in its inclusiveness and in-depth analysis of the methods and findings 
from economic and cost of illness studies. We are unaware of any other review of the economic 
evidence in MND, but acknowledge some unpublished articles such as HTA reports in jurisdictions 
outside the UK may have been omitted. We excluded non-English studies, which may have been 
available to European, Latin American and Asian reimbursement authorities (for instance in relation 
to riluzole). 
The challenges presented in this review highlight the current methodological limitations faced by 
health economists in MND. These issues, such as the need to incorporate the broader impact of 
treatments on patients’ QoL and the uncertainty surrounding the current empirical evidence, 





indicate that the issues pertinent to the economic analysis of MND treatments are far reaching, and 
require due consideration in other health economic work. 
5. Conclusion  
Current economic studies in MND are limited in many ways, including the comprehensiveness and 
reliability of cost studies, a lack of research reporting health state utilities across the disease course, 
and poorly defined health states. Our review has highlighted a clear need for up to date and 
methodologically rigorous economic data for unbiased assessment of the cost-effectiveness of 
future interventions in MND. We have also identified a need for a robust evaluation framework in 
MND. Future research should target these limitations, and utilise data from large, longitudinal 
studies, such as the UK Trajectories of Outcome in Neurological Conditions (TONiC) study [76], which 
has recruited over 800 patients to complete cost and quality of life questionnaires. Improvements in 
economic studies in MND will result in more informative guidance on healthcare resource allocation 
when new, and inevitably expensive, interventions are licensed. 
6. Data Availability Statement 




1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. 
Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. 
2. Hogg, KE, Goldstein LH, Leigh PN. The psychological impact of motor neurone disease. Psychol 
Med. 1994;24(3):625-32. 
3. Talbot K. Motor neuron disease: the bare essentials.  Pract Neurol 2009;9:303-309. 
4. Miyashita M, Narita Y, Sakamoto A, Kawada N, Akiyama M, Kayama M, Suzukamo Y, Fukuhara S. 
Health-related quality of life among community-dwelling patients with intractable neurological 
diseases and their caregivers in Japan. Psychiatry Clin Neurosci. 2011;65(1):30-8. 
5. Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA. Global 
epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.  
Neuroepidemiology. 2013;41(2):118-30. 
6. National Institute for Health and Care Excellence. Motor neurone disease: assessment and 





7. Leigh PN, Abrahams S, Al-Chalabi A, Ampong MA, Goldstein LH, Johnson J, Lyall R, Moxham J, 
Mustfa N, Rio A, Shaw C, Willey E; King's MND Care and Research Team. The management of 
motor neurone disease. J Neurol Neurosurg Psychiatry. 2003;74 Suppl 4:iv32-iv47. 
8. Motor Neurone Disease Association. MND Treatment Trials 
http://www.mndassociation.org/research/mnd-research-and-you/treatment-trials/ (Accessed 
Aug 3, 2016) 
9. Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking 
reviews in health care. York: University of York; 2009. 
https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf (Accessed Aug 3, 2016). 
10. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. 
11. International Monetary Fund (IMF). Exchange Rate Archives. 
http://www.imf.org/external/np/fin/data/param_rms_mth.aspx (Accessed 17th October 2016) 
12. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. http://www.pssru.ac.uk/project-
pages/unit-costs/2015/index.php (Accessed 17th October 2016). 
13. Alanazy H, White C, Korngut L. Diagnostic yield and cost-effectiveness of investigations in 
patients presenting with isolated lower motor neuron signs. Amyotroph Lateral Scler 
Frontotemporal Degener. 2014;15(5-6):414-9. 
14. Vitacca M, Paneroni M, Trainini D, Bianchi L, Assoni G, Saleri M, Gilè S, Winck JC, Gonçalves MR. 
At Home and on Demand Mechanical Cough Assistance Program for Patients With Amyotrophic 
Lateral Sclerosis. Am J Phys Med Rehabil. 2010;89(5):401-6. 
15. Cruis K, Chernew M and Brown D. The cost-effectiveness of early noninvasive ventilation for ALS 
patients. BMC Health Serv Res. 2005;5:58. 
16. Tavakoli M. Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of 
riluzole by disease stage. Eur J Health Econ. 2002;3(3):156-65. 
17. Tavakoli M, Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral 
sclerosis in the UK. J Neurol Sci. 2001;191(1-2):95-102. 
18. National Institute for Health and Care Excellence. Riluzole (Rilutek) for the treatment of Motor 
Neurone Disease (TA20), 2001. 
19. Bryan S, Barton P, Burls A. The clinical effectiveness and cost effectiveness of riluzole for motor 
neurone disease – an update. Birmingham: West Midlands Development and Evaluations 





20. Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, Burls A. The clinical 
effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and 
systematic review. Health Technol Assess. 2001;5(2):1-97. 
21. Messori A, Trippoli S, Becagli P, Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral 
sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui 
Farmaci. Pharmacoeconomics. 1999;16(2):153-63. 
22. Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinas DF, Patrick DL. Cost effectiveness 
of recombinant human insulin-like growth factor I therapy in patients with ALS. 
Pharmacoeconomics. 1999;15(2):179-95.  
23. Ringel SP, Woolley JM, Culebras A. Economic analysis of neurological services. Eur J Neurol. 
1999;6 Suppl 2:s21-s24. 
24. Gray AM. ALS/MND and the perspective of health economics. J Neurol Sci. 1998;160 Suppl 1:S2-
5. 
25. Ginsberg GM, Lev B. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral 
sclerosis. Pharmacoeconomics. 1997;12(5):578-84. 
26. Booth-Clibborn N, Best L, Stein K. Riluzole for motor neurone disease. Development and 
Evaluation Committee Report No.73. Wessex Institute for Health Research and Development. 
1997. 
27. Chilcott J, Golightly P, Jefferson D et al. The use of riluzole in the treatment of amyotrophic 
lateral sclerosis. Sheffield: Trent Institute for Health Services Research. University of Leicester, 
Nottingham and Sheffield. 1997. 
28. Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, Gaspari C, Tandan R; ALS 
Center Cost Evaluation W/Standards & Satisfaction (Access) Consortium. Prospective study of 
cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) 
ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1-2):119-
27. 
29. Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, Kim SH. Socioeconomic costs of amyotrophic lateral 
sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 
2015;16(3-4):202-8 
30. Obermann M, Lyon M. Financial cost of amyotrophic lateral sclerosis: A case study. Amyotroph 
Lateral Scler Frontotemporal Degener. 2015;16(1-2):54-7. 
31. Connolly S, Heslin C, Mays I, Corr B, Normand C, Hardiman O. Health and social care costs of 
managing amyotrophic lateral sclerosis (ALS): An Irish perspective. Amyotroph Lateral Scler 





32. Athanasakis K, Kyriopoulos II, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating 
the economic burden of ALS in Greece: A cost-of-illness approach. Amyotroph Lateral Scler 
Frontotemporal Degener. 2015;16(1-2):63-4. 
33. Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: A 
Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 
2014;15(5-6):426-32. 
34. Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, Habeeb-Louks EM, Kennedy A, Cwik 
VA. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 
2014;49(3):431-8. 
35. Kang SC, Hwang SJ, Wu PY, Tsai CP. The utilization of hospice care among patients with motor 
neuron diseases: The experience in Taiwan from 2005 to 2010. J Chin Med Assoc. 
2013;76(7):390-4. 
36. Jennum P, Ibsen R, Pedersen SW, Kjellberg J. Mortality, health, social and economic 
consequences of amyotrophic lateral sclerosis: A controlled national study. J Neurol. 
2013;260(3):785-93. 
37. Muscular Dystrophy Association. Cost of Amyotrophic Lateral Sclerosis, Muscular Dystrophy, and 
Spinal Muscular Atrophy in the United States. Muscular Dystrophy Association, The Lewin Group 
Inc. 2012. https://www.mda.org/sites/default/files/Cost_Illness_Report.pdf  (Accessed Aug 3, 
2016) 
38. Lopes de Almeida JP, Pinto A, Pinto S, Ohana B, de Carvalho M. Economic cost of home-
telemonitoring care for BiPAP-assisted ALS individuals. Amyotroph Lateral Scler. 2012;13(6):533-
7. 
39. Vitacca M, Comini L, Assoni G, Fiorenza D, Gilè S, Bernocchi P, Scalvini S. Tele-assistance in 
patients with amyotrophic lateral sclerosis: Long term activity and costs. Disabil Rehabil Assist 
Technol. 2012;7(6):494-500. 
40. Ward AL, Sanjak M, Duffy K, Bravver E, Williams N, Nichols M, Brooks BR. Power wheelchair 
prescription, utilization, satisfaction, and cost for patients with Amyotrophic lateral sclerosis: 
Preliminary data for evidence-based guidelines. Arch Phys Med Rehabil. 2010;91(2):268-72. 
41. Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, 
Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R. Socioeconomic burden of amyotrophic lateral 






42. López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. 
Social economic costs and health-related quality of life in patients with amyotrophic lateral 
sclerosis in Spain. Amyotroph Lateral Scler. 2009;10(4):237-43. 
43. Elman LB, Stanley L, Gibbons P, McCluskey L. A cost comparison of hospice care in Amyotrophic 
lateral sclerosis and lung cancer. Am J Hosp Palliat Care. 2006;23(3):212-6. 
44. Forshew DA, Bromberg MB. A survey of clinicians’ practice in the symptomatic treatment of 
ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(4):258-63. 
45. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic 
lateral sclerosis. J Neurol Sci. 2001;191(1-2):151-4. 
46. Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hospitalization in amyotrophic lateral 
sclerosis: Causes, costs, and outcomes. Neurology. 2001;56(6):753-7. 
47. Munsat TL, Rivière M, Swash M, Leclerc C. Economic burden of amyotrophic lateral sclerosis in 
the United Kingdom. J Med Econ. 1998;1(1-4):235-45. 
48. Klein LM, Forshew DA. The economic impact of ALS. Neurology. 1996;47(4 Suppl 2):S126-9. 
49. Sevick MA, Kamlet MS, Hoffman LA, Rawson I. Economic cost of home-based care for ventilator-
assisted individuals. Chest. 1996;109(6):1597-606. 
50. Moss AH, Oppenheimer EA, Casey P, Cazzolli PA, Roos RP, Stocking CB, Siegler M. Patients with 
amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning 
and outcomes. Chest. 1996;110(1):249-55. 
51. Kiebert GM, Green C, Murphy C, Mitchell JD, O'Brien M, Burrell A, Leigh PN. Patients’ health-
related quality of life and utilities associated with different stages of amyotrophic lateral 
sclerosis. J Neurol Sci. 2001;191(1-2):87-93 
52. Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, Young C, Shaw PJ, Leigh PN, Turner 
MR, Steen IN, McCrone P, Al-Chalabi A. Health utility decreases with increasing clinical stage in 
amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3-
4):285-91. 
53. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with 
amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526-8. 
54. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC, Meininger V. A 
confirmatory dose-ranging study of riluzole in ALS. Neurology. 1996;47(6 Suppl 4):S242-50. 
55. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral 





56. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, 
Rudnicki SA. Effect of recombinant human insulin-like growth factor I on progression of ALS: a 
placebo-controlled study. Neurology. 1997;49(6):1621-30. 
57. Bradley W. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study 
Group (Phase III). Neurology. 1999 Apr 22;52(7):1427-33. 
58. Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations 
alongside Clinical Trials – Extrapolation with Patient-Level Data Report by the Decision Support 
Unit; 2014. 
59. Henriques A, Pitzer C, Schneider A. Neurotrophic Growth Factors for the Treatment of 
Amyotrophic Lateral Sclerosis: Where Do We Stand? Front Neurosci. 2010;4:32. 
60. Mitsumoto H. ALS Clinical Trials https://psg-
mac43.ucsf.edu/als/Mitsumoto,%20H%20(AAN)%208BS-006-97.pdf (Accessed Aug 3, 2016) 
61. Goutman SA, Chen KS, Feldman EL. Recent advances and the future of stem cell therapies in 
Amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):428-48. 
62. Scarrott JM, Herranz-Martín S, Alrafiah AR, Shaw PJ, Azzouz M. Current developments in gene 
therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2015;15(7):935-47. 
63. Al-Janabi H, Flynn TN, Coast J. QALYs and Carers. Pharmacoeconomics. 2011;29(12):1015-23. 
64. Rowen D, Dixon S, Hernández-Alava M, Mukuria C. Estimating informal care inputs associated 
with EQ-5D for use in economic evaluation. Eur J Health Econ. 2016;17(6):733-44. 
65. Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of 
the literature. Pharmacoeconomics. 2005;23(5):449-59. 
66. Epton J, Harris R, Jenkinson C. Quality of life in amyotrophic lateral sclerosis/motor neuron 
disease: A structured review. Amyotroph Lateral Scler. 2009;10(1):15-26. 
67. Jenkinson C, Peters M, Bromberg MB. Quality of life measurement in neurodegenerative and 
related conditions. Cambridge: Cambridge University Press, 2011. 
68. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. 
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient 
groups: A multi-country study. Qual Life Res. 2013;22(7):1717-27. 
69. Greene ME, Rader KA, Garellick G, Malchau H, Freiberg AA, Rolfson O. The EQ-5D-5L improves 
on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip 
Arthroplasty. Clin Orthop Relat Res. 2015;473(11):3383-90. 
70. Beusterien K, Leigh N, Jackson C, Miller R, Mayo K, Revicki D. Integrating preferences into health 
status assessment for amyotrophic lateral sclerosis: The ALS utility index. Amyotroph Lateral 





71. Goldstein LH, Adamson M, Jeffrey L, Down K, Barby T, Wilson C, Leigh PN. The psychological 
impact of MND on patients and carers. J Neurol Sci. 1998;160 Suppl 1:S114-21. 
72. Goldstein LH, Adamson M, Barby T, Down K, Leigh PN. Attributions, strain and depression in 
carers of partners with MND: A preliminary investigation. J Neurol Sci. 2000;180(1-2):101-6. 
73. Lerum SV, Solbrække KN, Frich JC. Family caregivers’ accounts of caring for a family member 
with motor neurone disease in Norway: A qualitative study. BMC Palliat Care. 2016;15:22. 
74. Hawton A, Shearer J, Goodwin E, Green C. Squinting through layers of fog: assessing the cost 
effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy. 
2013;11(4):331-41. 
75. Knapp M, Iemmi V, Romeo R. Dementia care costs and outcomes: a systematic review. Int J 
Geriatr Psychiatry. 2013;28(6):551-61. 
76. Trajectories of Outcomes in Neurological Conditions (TONiC) 
https://tonic.thewaltoncentre.nhs.uk/tonic-mnd (Accessed Aug 6, 2016). 
 
Table and Figure legends 
Table 1: Methods of economic evaluations in MND 
Table 2: Methods of cost studies in MND 
Table 3: Key cost and utility data in economic evaluations in MND  
Table 4: Principal direct and indirect cost data in cost studies in MND 
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7. exp cost benefit/  
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10. Quality Adjusted Life Year$ or QALY$ .mp.  
11. Life year$ gain* .mp.  
12.  cost*.kw.ti.ab 
13.  economic adj2 cost$.mp 
14.  Socioeconomic.mp 
15.  Productivity Costs or Absenteeism.mp 
16.  Healthcare cost$ or Cost$ of Illness.mp 
17.  exp cost analysis/ 
18.  financ*.ti.ab 
19. Utilit*.mp 
20. HSUV or Health State Utility Values.mp 
21. Standard Gamble.ti.ab 
22. Time Trade Off.ti.ab 
23. Visual Analogue Scale.ti.ab 
24. EQ-5D.ti.ab 
25. SF-36 or Short Form 36.ti.ab  
26. SF6D.ti.ab 
27. ALS Utility Index or Amyotrophic Lateral Sclerosis Utility Index 
28. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27  
29. exp Motor Neuron$ Disease 
30. Amyotrophic Lateral Sclerosis.mp.  





32. Progressive Muscular Atrophy.mp.  
33. Progressive Bulbar Palsy.mp.  
34. Primary Lateral Sclerosis.mp. 
35. Charcot Disease.mp. 
36. 29 or 30 or 31 or 32 or 33 or 34 or 35 




41. 38 or 39 or 40  
42. 37 not 41  
43. Limit 42 to English 
 
EconLit Search Strategy  
(MESH(ECON*) OR all((economic model OR discrete event simulation)) OR all((Markov* OR 
Incremental Cost Effectiveness Ratio)) OR all((cost benefit analysis OR cost effectiveness)) OR 
all((cost analysis OR cost utility)) OR all((QALY* OR quality adjusted life year*)) OR all(life year* 
gain*)) 
OR 
(TI,AB(cost*) OR all((Productivity OR absenteeism)) OR all((Healthcare cost* OR Cost Analysis)) OR 
all((cost of illness OR Direct costs)) OR all(Indirect costs) OR TI,AB(finac*)) 
OR 
(all(Utilit*) OR all((Health State Utility Values OR standard gamble)) OR all((time trade off OR EQ-5D)) 
OR all((visual analogue scale OR sf-36)) OR all((SF-6D)) OR all(ALS Utility Index)) 
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Year of Publication, 
(cost data year) 
Mean direct cost per patient 
(2015 cost in £)  
Health state utilities 
Alanazy, White and 
Korngut  
2014 (2013) [13] 
Canada  
Investigative testing: Can$ 10,686 (£5,861) 
(lifetime cost) 
 
Control: Standard care costs assumed equal in 
both groups 
None  
Vitacca et al   
2010 (2005) [14] 
Italy  
Tele assisted care: €425 (£369) per month 
 
Standard care:  €239 (£214) per month 
None  
Gruis, Chernew and 
Brown   
2005 (2003) [15] 
United States  
Non-invasive ventilation: $3,132 (£2,584) per 
annum 
 
Trial of non-invasive ventilation in patients who 
prove to be intolerant: $467 (£385) (lifetime cost) 
 
Control (Standard care): Standard care costs 
assumed in both groups 
Mild State: 0.8  
Moderate State: 0.6  
Severe State: 0.5  
Terminal State: 0.4 
Aventis Pharma  
2000 (1998) [18] 
and updates / 
revisions [16,17] 
United Kingdom               
Intervention (riluzole): £3,742 (£6,429) per 
annum + Standard care costs 
 
Control Group (Standard care annual costs):  
Mild State Care: £1,224 (£2,068) 
Moderate State Care: £805 (£1,360) 
Severe State Care: £1,754 (£2,963) 
Terminal State Care: £3,231 (£5,458)             
Mild State: 0.79 
Moderate State: 0.67  
Severe State: 0.71  
Terminal State: 0.45 
Bryan, Barton and 
Burls  
2000 (1999) [19] 
United Kingdom  
*Updated analysis 
of Stewart et al [20] 
Intervention (riluzole): £3,930 (£6,385) per 
annum + Standard care costs 
 
Control (Standard care annual costs):  
Mild state care: £1,237 (£2,056)  
Moderate state care: £834 (£1,352) 
Severe state care: £1,771 (£2,957) 
Terminal state care: £3,263 (£5,444) 
Mild State: 0.79 
Moderate State: 0.67  
Severe State: 0.71  
Terminal State: 0.45 
Stewart et al  
2000 (1999) [20] 
United Kingdom  
Intervention (riluzole): £10.21 (£16.59) per day; 
monitoring: £17 (£28) per month 
 
Control (Standard care annual costs):  
Mild state care: £1,237 (£2,056) 
Moderate state care: £834 (£1,352) 
Severe state care: £1,771 (£2,957) 
Terminal state care: £3,263 (£5,444) 
Mild State: 0.79  
Moderate State: 0.67 
Severe State: 0.71  
Terminal State: 0.45 
Messori et al  
1999 (1996) [21] 
Italy  
Intervention (riluzole): US$8,736 (£9,487) per 
annum 
 
Control: standard care costs assumed to be equal 
in both groups 
None 
Ackerman et al  
1999 (1996) [22] 
United States  
rhlGF-1 therapy: US$46,860 (£51,295) (lifetime 
cost) 
 
Control (Standard care): $7,754 (£8,494) (lifetime 
cost) 
Appel ALS score 40 - 59: 0.89  
Appel ALS score 60 - 86: 0.82  
Appel ALS score 87- 109: 0.41 
Appel ALS score 110 - 128: 0.01  
Appel ALS score 129 - 164: -0.53  
Ringel, Woolley and 
Wilkins  
1999 (1996) [23]        
United States  
Direct and Indirect costs of MND (per month): 
Forced Vital Capacity 90+: US$1,395 (£1,571):  
Forced Vital Capacity 60-90: US$1,770 (£1,994):  
Forced Vital Capacity 30-60: US$3,046 (£3,441)  
Forced Vital Capacity 0-30: US$4,746 (£5,345) 
Forced Vital Capacity 90+: 0.9  
Forced Vital Capacity 60-90: 0.8  
Forced Vital Capacity 30-60: 0.6  
Forced Vital Capacity 0-30: 0.4 
(hypothetical values)  
Gray  
1998 (1997) [24] 
United Kingdom  
Intervention (riluzole): 
Non-tracheostomy patients: £286 (£491) per 
month; patients post-tracheostomy:  
£300 (£504) per month 
  
Control (Standard care): standard care costs 
assumed equal in both groups 
Various scenarios: survival time 
with utilities of 1, 0.8 and 0.5 
(hypothetical values) 
Ginsberg and Lev  
1997 (1996) [25] 
Isreal  





Chilcott et al  
1997 (1996) [26] 
United Kingdom   
Intervention (riluzole): £3,720 (£6,568) per 
annum 
 
Control (Standard care): Standard care costs 
assumed to be equal in both groups 
None 
Booth-Clibborn et al 
1997 (1996) [27] 
United Kingdom                  
Intervention (riluzole): £15,000 (£25,771) 
(lifetime costs) 
Control (Standard care): Standard care costs 





Year of Publication, 
(cost data year) 
Mean direct cost per patient 
(2015 cost in £)  
Mean indirect cost per patient (2015 
cost in £)  
Boylan et al  
2016 (2007) [28] 
United States  
Clinic costs: $507 (£497) per clinic visit Not considered 
Oh et al  
2015 (2013) [29] 
South Korea  
Healthcare costs (per month): 
Stage 1: Not stated 
Stage 2: $3,181 (£2,027) 
Stage 3: $2,773 (£1,767) 
Stage 4: $4,415 (£2,722) 
Patient lost wages (per month): 
Stage 1: Not stated 
Stage 2: $1,155 (£736) 
Stage 3: $1,889 (£1,204) 
Stage 4: $2,629 (£1,675) 
Obermann and Lyon  
2015 (2005) [30] 
United States  
Ventilation: $212,430 (£157,372) 
(lifetime cost)  
Hospital Care: $114,558 (£84,866) 
(lifetime cost) 
Caregiver costs:  €669,150 (£495,719) 
(lifetime cost) 
Connolly et al  
2015 (2010) [31] 
Ireland  
Health and social care costs: €1,795 
(£1,255) per month 
Not considered  
Attanasalais et al  
2015 (2013) [32] 
Greece  
Direct medical costs: €4,305 (£2,830) 
per annum 
Informal care and productivity losses: 
€3,145 (£2,168) per annum 
Gladman et al  
2014 (2012) [33] 
Canada  
 
Healthcare provider and “out of pocket 
costs”: Can$32,337 (£21,455) per 
annum 
Lost wages of patients and caregivers: 
Can$56,821 (£37,700) per annum 
Larkindale et al  
2013 (2010) [34] 
United States  
Total direct and indirect costs per patient: $63,693 (£48,468) per annum (cost not 
disaggregated) 
King et al  
2013 (2007) [35] 
Taiwan  
Hospice care: NT$ 47,180 (£2,962) 
(lifetime cost) 
Not considered  
Jennum et al 
2013 (2009) [36] 
Denmark  
Medical costs: €18,918 (£16,514) per 
annum 
Spouse earnings: Increased €3,420 
(£2,985) per annum 
Muscular Dystrophy 
Association  
2012 (2010) [37] 
United States  
Medical costs: $30,934 (£23,165) per 
annum 
Not considered 
De Alemedia  




Tele monitoring care: €8,909 (£9,030) 
per annum 
 
Standard care: €19,952 (£19,952) per 
annum 
Not stated 
Vitacca et al  
2012 (2007) [39] 
Italy  
Tele assistance: €105 (£84) per month Not considered 
Ward et al  
2010 (2008) [40] 
United States  
Wheelchair costs: $26,404 (£20,481) 
(lifetime cost) 
Not considered 
Schepelmann et al  
2010 (2009) [41] 
Germany  
Medical costs: €14,980 (£13,076) per 
annum 
Patient lost earnings: €21,400 (£18,680) 
per annum 
Lopez-Bastida et al  
2009 (2004) [42] 
Spain  
Medical costs (lifetime costs): 
High severity patients: €34,729 
(£31,182) 
Low severity patients: €6,735 (£6,034) 
High severity patients: €8,000 (£7,168) 
Low severity patients: €10,265 (£9,198) 
Elman et al  
2006 (2003) [43] 
United States  
Hospital stay costs: $5,623 (£5,416) 
(lifetime cost) 
Not considered 
Forshew and Bromberg  
2003 (2002) [44] 
United States  
Various drug costs Not considered  
Wasner et al  
2001 (2000) [45] 
Germany  
Alternative medicines: €4,142 (£4,293) 
(lifetime cost) 
Not considered 
Lechtzin et al  
2001 (1996) [46] 
United States  
Hospital stay costs: $19,810 (£21,685) 
(lifetime cost) 
Not considered  
Munsat et al  
1998 (1996) [47] 
United Kingdom  
Standard care costs (per annum) 
Mild State Care: £1,185 (£2,072)  
Moderate State Care: £800 (£1,370) 
Severe State Care: £1,698  (£2,989) 
Terminal State Care: £3,128 (£5,498) 
Not considered 
Klein and Forshew  
1996 (1995) [48] 
United States 
Diagnosis costs: $10,000 - $ 20,000  
(£10,946 - £21,893) (lifetime cost) 
Mechanical Ventilation: $199,500 
(£218,382) per annum 
Not considered 
De Alemedia  
2012 (2010) [38] 
Spain 
Home ventilation: $91,704 (£101,997) 
per annum 
Home renovations: $5,676 (£6,314): 
(lifetime cost) 
Caregiver lost wages: $7,008 (£7,671) 
per annum 
Moss et al  
1996 (1995) [50] 
United States  
Ventilation in hospital: $366,852 
(£401,570) per annum 



















































Full-text articles excluded, 
with reasons (n = 20)
Lacking in outcomes, costs 
and comparator (n=5) 
Lack of detailed costs (n=4)
Lack of HSUVs (n=11)
Studies included in review (n=43)
